TLSI — TriSalus Life Sciences, Inc.

Summary of TriSalus Life Sciences Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $13.2 million, a 60% increase year-over-year from $8.3 million.
• Full Year Revenue: $45.2 million, up 53% from the previous year.
• Gross Margin: 87% for Q4, up from 85% in the prior year.
• Net Operating Loss: $3.3 million for Q4, improved from $7.6 million year-over-year.
• Adjusted EBITDA Loss: Approximately $950,000 for Q4, significantly better than a loss of $5.7 million in Q4 2024.
• Cash and Cash Equivalents: $20.4 million as of December 31, 2025, bolstered by a $46 million public offering completed in February 2026.

2. Strategic Updates and Business Highlights

• Product Expansion: TriSalus expanded its TriNav product suite from 2 to 7 offerings, enhancing its appeal to interventional radiologists.
• Clinical Studies: Investment in foundational clinical studies for the PEDD platform is underway to validate its clinical and economic differentiation.
• Commercial Infrastructure: A significant expansion of the sales force is planned, with a focus on doubling the commercial organization to enhance market coverage and sales productivity.
• New Applications: The company is exploring non-liver applications, including thyroid and uterine artery embolization, with promising early feedback and clinical data.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: TriSalus expects revenues between $60 million and $62 million, with a revenue split of approximately 40% in the first half and 60% in the second half, reflecting the impact of sales force expansion and new product launches.
• Product Launches: Anticipation of launching TriNav Advance in the first half of 2026, which is expected to enhance market penetration and mapping capabilities.

4. Challenges and Points of Concern

• Delayed Clinical Data: The release of updated clinical data for the nelitolimod program has been postponed to the second half of 2026, which may impact investor sentiment.
• Increased Operating Losses: While losses have decreased year-over-year, the company reported a basic and diluted loss per share of $1.84, up from $1.31, indicating ongoing financial strain.
• Market Competition: The company faces competitive pressures in both liver and non-liver markets, necessitating continued innovation and effective marketing strategies.

5. Notable Q&A Insights

• Growth Contribution: Management indicated that liver applications will continue to dominate revenue in 2026, but they expect meaningful contributions from new applications in the second half of the year.
• Sales Organization Structure: The sales organization will be significantly expanded, including a new layer of management to improve efficiency and support growth.
• Mapping Growth: The introduction of new products like TriNav XP and TriNav Advance is expected to enhance mapping capabilities, which could drive additional revenue growth.
• Physician Adoption: There is a trend of physicians using TriSalus products across various applications, suggesting potential for cross-selling and increased utilization of the full product suite.

Overall, TriSalus Life Sciences demonstrated strong revenue growth and strategic initiatives aimed at expanding its market presence, despite facing challenges related to clinical data delays and ongoing financial losses.